Prediction of unbound mycophenolic acid concentrations in patients after hematopoietic cell transplantation

Therapeutic Drug Monitoring

Volumn 29, Issue 4, 2007, Pages 385-390

  Huang, Jiayin ^a   Jacobson, Pamala ^a   Brundage, Richard ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Hematopoietic cell transplant; Mycophenolic acid; Mycophenolic acid glucuronide; Protein binding; Unbound concentration

Indexed keywords

BILIRUBIN; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; GRAFT REJECTION; HEMATOPOIETIC CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; PRODRUGS; PROTEIN BINDING; REGRESSION ANALYSIS; SERUM ALBUMIN;

EID: 34547678082     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318074d979     Document Type: Article

References (19)

1. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995;41:1011-1017.
2. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925-929.
3. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998;9:1511-1520.
4. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999;126:1075-1082.
5. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
6. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005;78:486-500.
7. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol. 2005;59:271-280.
8. Mudge DW, Atcheson BA, Taylor PJ, et al. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004;26:453-455.
9. Jacobson PA, Green KG, Hering BJ. Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol. 2005;45:901-909.
10. Matz R. Cockcroft-Gault equation and estimation of creatinine clearance. Am J Med. 2002;112:684; author reply 684-685.
11. Jacobson P, Green K, Rogosheske J, et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol. 2007;47:6-12.
12. Beck DE, Farringer JA, Ravis WR, et al. Accuracy of three methods for predicting concentrations of free phenytoin. Clin Pharmacol. 1987;6:888-894.
13. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002;13:759-768.
14. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998;38:268-275.
15. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
16. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit. 2000;22:27-30.
17. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999;39:715-720.
18. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol. 2003;21:2633-2635.
19. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit. 2004;26:284-286.